Intercept Pharmaceuticals vs. Zenara Pharma: ANDA Patent Consolidation in FXR Agonist Litigation
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private, Ltd. |
| Numéro de dossier | 1:23-cv-00714 (D. Del.) |
| Tribunal | District of Delaware, before Judge Maryellen Noreika |
| Durée | June 30, 2023 – March 6, 2024 250 days |
| Résultat | Procedural Resolution – Consolidation |
| Brevets en cause | |
| Produits incriminés | Zenara Pharma’s proposed generic version of Ocaliva® (obeticholic acid) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Innovator pharmaceutical company and developer of Ocaliva® (obeticholic acid), a key FXR agonist therapy for primary biliary cholangitis (PBC).
🛡️ Défendeur
Generic pharmaceutical manufacturer seeking regulatory approval for a generic version of Ocaliva® via an ANDA pathway.
Le brevet en cause
This Hatch-Waxman infringement action centered on **U.S. Patent No. RE48,286**, a reissue patent covering steroids as agonists for the Farnesoid X Receptor (FXR), the active mechanism behind Intercept’s branded bile acid therapy Ocaliva® (obeticholic acid). Reissue patents are granted by the USPTO to correct defects in originally issued patents.
- • US RE48,286 — Steroids as agonists for FXR (Farnesoid X Receptor)
Vous développez un composé pharmaceutique similaire ?
Identify potential blocking patents in the FXR agonist space before development.
Le verdict et l'analyse juridique
Résultat
This case was resolved through **consolidation**, not a trial verdict or settlement on the merits. The action (1:23-cv-00714) was merged into the lead case (C.A. No. 22-1215) for all purposes. No damages were awarded, and no injunctive relief was independently granted within this docket — the substantive merits of infringement and validity remain live issues within the consolidated proceeding.
Principales questions juridiques
The consolidation reflects several critical legal and strategic dynamics. The most significant outcome is the **extension of Hatch-Waxman exclusivity protection**. By timely suing on RE48,286, Intercept secured a *separate* 30-month stay running to December 21, 2025, effectively delaying potential generic market entry. This also streamlined a complex multi-patent dispute under a unified protective order and scheduling framework before Judge Maryellen Noreika in the District of Delaware.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in pharmaceutical development, especially in the FXR agonist space. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige pharmaceutique.
- View all 7 related Ocaliva® patents
- Analyze Intercept’s patent portfolio for FXR agonists
- Understand Hatch-Waxman stay architecture
🔍 Vérifier les risques liés à mon produit
Run a comprehensive FTO analysis for your own pharmaceutical compound or drug product.
- Input your compound structure or mechanism of action
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenez une évaluation concrète des risques de contrefaçon
Zone à haut risque
FXR agonist compounds and methods
Extended Stay Secured
Until December 2025 for RE48,286
Consolidated Discovery
Efficiency for multi-patent suits
✅ Points clés à retenir
Timely assertion against successively filed Paragraph IV certifications can yield independent 30-month stays, extending exclusivity.
Rechercher des affaires liées à la loi Hatch-Waxman →Reissue patents introduce unique validity risks (recapture, intervening rights) for generic challengers to assess.
Découvrez les analyses relatives aux brevets réémis →Foire aux questions
The case involved U.S. Patent No. RE48,286, a reissue patent covering steroids as agonists for FXR, listed in the Orange Book for Ocaliva® (obeticholic acid). The consolidated lead case (C.A. No. 22-1215) involves six additional Orange Book patents.
The parties stipulated to consolidation for judicial efficiency. All substantive infringement and validity issues relating to RE48,286 are being litigated within the lead case, C.A. No. 22-1215, before Judge Noreika.
It demonstrates that successive Orange Book patent listings paired with timely Hatch-Waxman suits can extend stay protections by years, materially delaying generic competition in specialty pharmaceutical markets.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Case Docket – C.A. No. 22-1215 (D. Del.)
- USPTO Patent RE48,286
- FDA Orange Book – Ocaliva®
- U.S. Patent and Trademark Office — Reissue Patent Resources
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.